FI3902803T3 - Atsaheterobisyklisiä mat2a:n inhibiittoreita ja käyttömenetelmiä syövän hoitamiseksi - Google Patents
Atsaheterobisyklisiä mat2a:n inhibiittoreita ja käyttömenetelmiä syövän hoitamiseksi Download PDFInfo
- Publication number
- FI3902803T3 FI3902803T3 FIEP19845796.2T FI19845796T FI3902803T3 FI 3902803 T3 FI3902803 T3 FI 3902803T3 FI 19845796 T FI19845796 T FI 19845796T FI 3902803 T3 FI3902803 T3 FI 3902803T3
- Authority
- FI
- Finland
- Prior art keywords
- ochf
- koi
- nay
- chf
- joka
- Prior art date
Links
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 claims 6
- WRDDUWAOAXNARV-UHFFFAOYSA-N 2-[2-acetamido-4-(4-chlorophenyl)-1,3-thiazol-5-yl]acetic acid Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(Cl)=CC=2)=C1CC(O)=O WRDDUWAOAXNARV-UHFFFAOYSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 241000252073 Anguilliformes Species 0.000 claims 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101000725884 Homo sapiens Uncharacterized protein C20orf203 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101100128278 Mus musculus Lins1 gene Proteins 0.000 claims 1
- 235000009337 Spinacia oleracea Nutrition 0.000 claims 1
- 244000300264 Spinacia oleracea Species 0.000 claims 1
- 102100028651 Tenascin-N Human genes 0.000 claims 1
- 101710087911 Tenascin-N Proteins 0.000 claims 1
- 102100027600 Uncharacterized protein C20orf203 Human genes 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- BBXRRTJNJCPGBU-UHFFFAOYSA-N beta-naphthyl N-acetylphenylalaninate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)C(NC(=O)C)CC1=CC=CC=C1 BBXRRTJNJCPGBU-UHFFFAOYSA-N 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 238000005430 electron energy loss spectroscopy Methods 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 108010087204 oncoimmunin-M Proteins 0.000 claims 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 101150041594 soti gene Proteins 0.000 claims 1
- 235000014347 soups Nutrition 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3902803T3 true FI3902803T3 (fi) | 2023-04-25 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19845796.2T FI3902803T3 (fi) | 2018-12-27 | 2019-12-27 | Atsaheterobisyklisiä mat2a:n inhibiittoreita ja käyttömenetelmiä syövän hoitamiseksi |
Country Status (38)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN115960098B (zh) * | 2020-09-11 | 2026-04-10 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| WO2022143864A1 (zh) * | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| DE102021102487A1 (de) * | 2021-02-03 | 2022-08-04 | Aixinno Limited | Verfahren zum Handhaben biologischer Zellkulturen |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| JP7721686B2 (ja) * | 2021-06-02 | 2025-08-12 | 南京正大天晴制薬有限公司 | メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 |
| CN118434722A (zh) | 2021-10-20 | 2024-08-02 | 英矽智能科技知识产权有限公司 | 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途 |
| MX2024007457A (es) * | 2021-12-17 | 2024-08-27 | Tango Therapeutics Inc | Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas. |
| CN118414338A (zh) * | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| CN118742550B (zh) * | 2022-03-11 | 2025-09-05 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| AU2023299635A1 (en) | 2022-06-27 | 2025-01-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Tricyclic compounds and uses thereof |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| EP4582423A1 (en) | 2022-10-13 | 2025-07-09 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| CN121241050A (zh) * | 2023-03-06 | 2025-12-30 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| WO2024255802A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| CA2826034A1 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| UA125852C2 (uk) * | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| HUE066282T2 (hu) | 2018-03-30 | 2024-07-28 | Servier Lab | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra |
| AU2019414446A1 (en) * | 2018-12-27 | 2021-07-15 | Les Laboratoires Servier Sas | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| AR119046A1 (es) * | 2019-05-31 | 2021-11-17 | Agios Pharmaceuticals Inc | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer |
-
2019
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 KR KR1020257020196A patent/KR20250093588A/ko active Pending
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 KR KR1020217023828A patent/KR102823567B1/ko active Active
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en not_active Ceased
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 PH PH1/2021/551490A patent/PH12021551490A1/en unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 GE GEAP202315703A patent/GEAP202315703A/en unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 MY MYPI2021003553A patent/MY206578A/en unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 SM SM20230109T patent/SMT202300109T1/it unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 CA CA3124952A patent/CA3124952C/en active Active
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-06-27 JO JOJO/P/2021/0172A patent/JOP20210172B1/ar active
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
-
2024
- 2024-08-05 US US18/794,610 patent/US20250214988A1/en active Pending
-
2025
- 2025-07-04 JP JP2025113748A patent/JP2025133887A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220230A (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
| DOP2011000057A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| WO2001074376A3 (en) | Cathepsin inhibitors in cancer treatment | |
| ES2180622T3 (es) | Oligonucleotidos antisentido con actividad inhibidora de tumorigenicidad. | |
| EP1280802A4 (en) | SUBSTITUTED INDAZOLES WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS CELL PROLIFERATION INHIBITORS | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| NZ599997A (en) | Seed treatment compositions and methods | |
| AR035482A1 (es) | Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos | |
| HN2001000005A (es) | Nuevos compuestos fungicidas | |
| WO2005044181A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| CO6160236A2 (es) | Inhibidor de quinasa | |
| MA31358B1 (fr) | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone | |
| NO20070498L (no) | Armering | |
| WO2014194030A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| MX2012000711A (es) | Inhibidores de pirrolopirazina de cinasas. | |
| MX2010004897A (es) | Forma de dosificacion oralmente desintegrada. | |
| AR032526A1 (es) | Una composicion, polimeros dispersables en agua, un metodo para hacer los mismos y articulos usando los mismos | |
| MX2019000661A (es) | Nuevos analogos de urocortina-2 modificados con acido graso para el tratamiento de diabetes y enfermedad renal cronica. | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| WO2008086269A3 (en) | 6-aminoisoquinoline compounds useful as kinase modulators | |
| MY161243A (en) | Fluorinated aminotriazole derivatives | |
| BRPI0606463A2 (pt) | derivados triazol substituìdos com antagonistas de oxitocina | |
| CO5180597A1 (es) | Composiciones anhidras utiles como filtros para rayos ultra violeta con un factor de proteccion solar alto | |
| BR0115936A (pt) | 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe | |
| MX2018014176A (es) | Capsulas que comprenden bencilpropargileteres para usar como inhibidores de la nitrificacion. |